Table 3 Patients’ treatment regimens and outcomes
All patients (n = 475) | Survivors (n = 428) | Non-survivors (n = 47) | p-value | |
|---|---|---|---|---|
Duration of hospitalization (days) | 10 (6–14) | 9 (6–13) | 15 (8–27) | < 0.001 |
Withdrawal of IS agent | ||||
Calcineurin inhibitors | 49 (10.3) | 32 (7.5) | 17 (36.2) | < 0.001 |
Antimetabolites | 428 (90.1) | 386 (90.2) | 42 (89.3) | |
Treatment of infection | ||||
Hydroxychloroquine | 105 (22.1) | 95 (22.2) | 10 (21.3) | 0.89 |
Favipiravir | 391 (82.3) | 346 (80.8) | 45 (95.7) | 0.005 |
Oseltamivir | 26 (5.5) | 24 (5.6) | 2 (4.3) | 0.514 |
Cytokine‐targeted therapy | ||||
Anakinra | 18 (3.8) | 14 (3.3) | 4 (8.5) | 0.09 |
Tocilizumab | 14 (3.4) | 11 (2.6) | 3 (6.4) | 0.152 |
Convalescent plasma | 21 (4.4) | 14 (3.3) | 7 (14.9) | < 0.001 |
IVIG | 17 (3.6) | 12 (2.8) | 5 (11.3) | 0.02 |
Anticoagulation | 344 (72.4) | 303 (70.8) | 41 (87.2) | 0.026 |
Antibiotics | 248 (52.2) | 216 (50.5) | 32 (68.1) | 0.032 |
Ventilation devices | ||||
Nasal cannula | 158 (33.2) | 158 (36.9) | 0 | < 0.001 |
Non-invasive ventilation | 25 (5.3) | 24 (5.6) | 1 (2.1) | < 0.001 |
Mechanical ventilation | 53 (11.2) | 7 (1.6) | 46 (97.9) | < 0.001 |
Acute kidney injury | 168 (35.3) | 130 (30.4) | 38 (80.9) | < 0.001 |
Stage 1 | 87 (18.3) | 73 (17.1) | 14 (29.8) | 0.032 |
Stage 2 | 35 (7.4) | 26 (6.1) | 9 (19.2) | 0.003 |
Stage 3 | 46 (9.7) | 31 (7.2) | 15 (31.9) | < 0.001 |
Cytokine storm | 56 (11.8) | 30 (7) | 26 (55.3) | < 0.001 |
ARDS | 80 (16.8) | 34 (7.9) | 46 (97.9) | < 0.001 |
Hospitalization | 195 (41.1) | 195 (45.6) | 0 | < 0.001 |
ICU admission | 69 (14.5) | 23 (5.4) | 46 (97.9) | < 0.001 |